Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pramodini MedicareNSE:PRAMODINI -2.01%19 EBITDA Margin % is 50.52% as of Mar. 2026, which is 1% above its 10-year median of 50.13. GuruFocus rates NSE:PRAMODINI with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 671 Healthcare Providers & Services companies, Pramodini Medicare ranks better than 97.76% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Pramodini Medicare's EBITDA for the
three
months ended in Mar. 2026 was ₹90.1 Mil. Pramodini Medicare's Revenue for the
three
months ended in Mar. 2026 was ₹178.3 Mil. Therefore, Pramodini Medicare's EBITDA margin for the quarter that ended in Mar. 2026 was 50.52%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pramodini Medicare EBITDA Margin % Related Terms
Pramodini Medicare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Pramodini Medicare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pramodini Medicare EBITDA Margin % Chart
Pramodini Medicare Annual Data
Trend
Mar23
Mar24
Mar25
Mar26
EBITDA Margin %
49.16
45.65
55.38
51.10
Pramodini Medicare Quarterly Data
Mar23
Mar24
Mar25
Dec25
Mar26
EBITDA Margin %
0.00
0.00
0.00
0.00
50.52
NSE:PRAMODINI vs HCA, THC, EHC: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Pramodini Medicare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pramodini Medicare EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pramodini Medicare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pramodini Medicare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pramodini Medicare (NSE:PRAMODINI) has a EBITDA Margin % of 50.52% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pramodini Medicare and its competitors. This is near median its historical median of 50.13. Over the past decade, Pramodini Medicare's EBITDA Margin % has ranged from 45.65 to 55.38. According to the industry distribution chart, Pramodini Medicare ranks #15 out of 671 companies in the Healthcare Providers & Services industry, placing it in the top 2.2%.
Is Pramodini Medicare's EBITDA Margin % too high?
Pramodini Medicare's current EBITDA Margin % of 50.52% is near median its 10-year median of 50.13. Over the past 10 years, this metric has ranged from a low of 45.65 to a high of 55.38. The Healthcare Providers & Services industry median EBITDA Margin % is 10.09. Pramodini Medicare's value of 50.52% is 400.7% above this industry median. Based on the distribution chart, Pramodini Medicare ranks #15 out of 671 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Pramodini Medicare has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pramodini Medicare's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Pramodini Medicare ranks #15 out of 671 companies for EBITDA Margin %. This places Pramodini Medicare in the top 2% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.09. Pramodini Medicare's value of 50.52% is 400.7% above this benchmark. Historically, Pramodini Medicare's own EBITDA Margin % has ranged from 45.65 to 55.38 over the past decade. While the company's 10-year median is 50.13 vs. the industry median of 10.09, Pramodini Medicare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.09, based on 671 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pramodini Medicare's current EBITDA Margin % of 50.52% is 400.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pramodini Medicare and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pramodini Medicare's current EBITDA Margin % is 50.52%, which is near median its own 10-year median of 50.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pramodini Medicare stock overvalued right now?
Pramodini Medicare (NSE:PRAMODINI) has a current EBITDA Margin % of 50.52%. The current EBITDA Margin % is 50.52%, which is near median its 10-year median of 50.13 and 400.7% above the Healthcare Providers & Services industry median of 10.09. Pramodini Medicare's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pramodini Medicare (NSE:PRAMODINI), the current EBITDA Margin % is 50.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pramodini Medicare Ltd is a diagnostic service provider in India. It provides a range of technology-enabled diagnostic services such as radiology, clinical laboratory and nuclear medicine service to public hospitals, private hospitals, certain PSU (Public Sector Undertaking) of Government of India and medical colleges across tier I, tier II and tier III cities throughout India. The company also provide teleradiology services, which functions on a 24*7 basis throughout the year. It provides healthcare services for core testing, patients diagnosis, disease prevention and monitoring of various health conditions. Its services includes both routine and specialized tests, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of diseases.
19GF Score
Get the complete analysis for NSE:PRAMODINI
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:PRAMODINI has been successfully added to your 
